Market revenue in 2023 | USD 3,722.2 million |
Market revenue in 2030 | USD 11,408.5 million |
Growth rate | 17.4% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 85.51% in 2023. Horizon Databook has segmented the Canada precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
In Canada, a major barrier to advancing PM is the sharing and combining of data across jurisdictions, rather than the data collection itself. The promise of personalized medicine is within reach through the Canadian Partnership for Tomorrow’s Health project (Can Path), the largest population health cohort in Canada.
Can Path has made significant progress in integrating clinical, environmental, and population level health data across all provinces, providing a national access point to deeply characterized and longitudinal health and lifestyle information, unmatched by any other entity in Canada.
In partnership with Adela, CanPath will generate genomic data to be hosted alongside clinical and population data of consented participants from across Canada within a secure digital framework. This Digital Secure Health platform has the potential to position Canada at the forefront of genomic medicine globally, supporting the development of the biotechnology sector, industry research, and harmonization with leading precision medicine programs.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into Canada precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account